Breast cancer, screening and diagnostic tools: All you need to know. (January 2021)

• Record Type: Journal Article
• Authors: Barba, Diego; León-Sosa, Ariana; Lugo, Paulina; Suquillo, Daniela; Torres, Fernando; Surre, Frederic; Trojman, Lionel; Caicedo, Andrés
• Is Part Of: Critical reviews in oncology/hematology. Volume 157(2021)
• Publication Date: 2021-01
• Subjects: ACCE analytical validity, clinical validity, clinical utility, ethical, legal, and social implications -- ACS American Cancer Society -- ADC apparent diffusion coefficient -- AI artificial intelligence -- AIB1 coactivator amplified in breast cancer 1 -- AJCC American Joint Committee on Cancer -- ACR American College of Radiology -- anti-CTLA-4 anti-cytotoxic t-lymphocyte-associated protein 4 -- anti-PD1 anti-programmed cell death protein 1 -- anti-PD-L1 anti-programmed cell death-1 ligand 1 -- AR androgen receptor -- ARFI Acoustic Radiation Force Impulse Imaging -- ASCO American Society of Clinical Oncology -- BCSC Breast Cancer Surveillance Consortium -- BI-RADS Breast Imaging-Reporting and Data System -- BMI body mass index -- BPx breast physical examination -- BCS breast cancer screening -- CAD computer-aided detection -- CAFs cancer-associated fibroblasts -- CBE clinical breast examination -- CDC Centers for Disease Control and Prevention -- CEM contrast-enhanced mammography -- CE-MRI contrast enhanced-mri -- Chi3L1 chitinase 3-like 1 -- CSCs cancer stem cells -- ctDNA circulating tumor DNA -- CTS clinical treatment score -- CTX Chemotherapy -- CXCL4 chemokine (c-x-c motif) ligand 4 -- DBT digital breast tomosynthesis -- DCIS ductal carcinoma in situ -- DNA deoxyribonucleic acid -- DITI digital infrared thermography imaging -- DOT diffuse optical tomography -- DW-MRI diffusion weighted-MRI -- ECIBC european breast guidelines of the european commission initiative on breast cancer -- EGFR epidermal growth factor receptor -- EMT epithelial to mesenchymal transition -- EORTC European Organization for Research and Treatment of Cancer -- EPclin® endopredict clinical® -- ER+/- estrogen/estradiol receptor positive/negative -- EREs estrogen response elements -- ERRs α/β/γ estrogen-related receptors α/β/γ -- ESMO European Society for Medical Oncology -- EXET extended endocrine trial -- EXOs Exosomes -- FES 16α-18F-fluoro-17β-estradiol -- FDA Food and Drug Administration -- FDG Fluorodeoxyglucose -- FDS Fiberoptic ductoscopy -- FFA Free Fatty Acids -- FFDM full-field digital mammography -- GEP/S gene expression profiling/signatures -- GLOBOCAN Global Cancer Observatory -- HbT hydrogen breast test -- HDA1 histone deacetylase 1 -- HER1/2/3 +/- human epidermal growth factor receptor 1/2/3 positive/negative -- HR+/- hormone receptor positive/negative -- HT hormonal therapy -- IDC invasive ductal carcinoma -- IDO indoleamine 2, 3-dioxygenase -- IHC Immunohistochemistry -- IHC4 Immunohistochemical 4 -- IL Interleukin -- IoT internet of things -- IR InfraRed -- LCIS lobular carcinoma In Situ -- LN+/- lymph-nodes positive/negative -- mAbs monoclonal antibodies -- MHC-I major histocompatibility complex i -- MINDACT microarray in node-negative disease may avoid chemotherapy trial -- miRNAs MicroRNAs -- ML Machine Learning -- MRE magnetic resonance elastography -- MRI magnetic resonance imaging -- MSCs mesenchymal stem cells -- mTOR mammalian target of rapamycin -- NADH reduced nicotinamide adenine dinucleotide -- NCCN National Comprehensive Cancer Network -- N-CoR nuclear receptor co-repressor -- NmU Neuromedin U -- OCT Optical Coherence Tomography -- PET/CT positron emission tomography/computed tomography -- PGC1α/1β peroxisome proliferator-activated receptor gamma co-activator 1α/1β -- PPARγ peroxisome proliferator-activated receptor-γ -- PR+/- progesterone receptor positive/negative -- RASTER microarRAy-prognoSTics-in-breast-cancER -- ROI region of interest -- ROS reactive oxygen species -- RTK receptor tyrosine kinase -- SBI Society of Breast Imaging -- SEER surveillance, epidemiology and end results -- SG St. Gallen International Breast Cancer Conference -- SND spontaneous nipple discharge -- SoC system-on-chip -- STAT3 signal transducer and activator of transcription 3 -- StO2 oxygen saturation -- TA-MUC1 tumor-associated transmembrane glycoprotein mucin 1 -- 99mTc-MIBI technetium-99m sestamibi -- TFF1 Trefoil Factor 1 -- TMA tissue microarray -- TME tumor microenvironment -- TNM tumor, node and metastasis -- TransATAC trial trans arimidex, tamoxifen, alone or in combination trial -- UCPs uncoupling proteins -- US United States -- USPSTF U.S. Preventive Services Task Force -- VEGF vascular endothelial growth factor -- YAP yes-associated protein; Breast cancer -- Screening -- Diagnosis -- Tools -- Mammography -- Biopsy -- Genetic profiling -- Artificial intelligence; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2020.103174
• Languages: English
• ISSNs: 1040-8428

Abstract

Graphical abstract: Highlights: Nearly two million cases of breast cancer are diagnosed each year worldwide. Multidisciplinary approaches are used to develop screening and diagnostic tools. Key information is provided on breast cancer for medical and research professionals. Breast cancer biology, standard and innovative detection tools are presented. This information is needed to develop better diagnostic and screening tools. Abstract: Breast cancer is one of the most frequent malignancies among women worldwide. Methods for screening and diagnosis allow health care professionals to provide personalized treatments that improve the outcome and survival. Scientists and physicians are working side-by-side to develop evidence-based guidelines and equipment to detect cancer earlier. However, the lack of comprehensive interdisciplinary information and understanding between biomedical, medical, and technology professionals makes innovation of new screening and diagnosis tools difficult. This critical review gathers, for the first time, information concerning normal breast and cancer biology, established and emerging methods for screening and diagnosis, staging and grading, molecular and genetic biomarkers. Our purpose is to address key interdisciplinary information about these methods for physicians and scientists. Only the multidisciplinary interaction and communication between scientists, health care professionals, technical experts and patients will lead to the development of better detection tools and methods for an improved screening and early diagnosis.